BACKGROUND: If women who receive the human papillomavirus (HPV) vaccine are unduly reassured about the cancer prevention benefits of vaccination, they may choose not to participate in screening, thereby increasing their risk for cervical cancer. This study assesses adult women's knowledge of the need to continue cervical cancer screening after HPV vaccination, describes Pap test intentions of vaccinated young adult women, and evaluates whether knowledge and intentions differ across groups at greatest risk for cervical cancer. METHODS: Data were from the 2008 Health Information National Trends Survey (HINTS) and the 2008 National Health Interview Survey (NHIS), which initiated data collection approximately 18 months after the first FDA approval of an HPV vaccine. We calculated associations between independent variables and the outcomes using chi-square tests. RESULTS: Of 1586 female HINTS respondents ages 18 through 74, 95.6% knew that HPV-vaccinated women should continue to receive Pap tests. This knowledge did not vary significantly by race/ethnicity, education, income, or healthcare access. Among 1101 female NHIS respondents ages 18-26 who had ever received a Pap test, the proportion (12.7%; n=139) who reported receipt of the HPV vaccine were more likely than those not vaccinated to plan to receive a Pap test within three years (98.1% vs. 92.5%, p<0.001). CONCLUSIONS: US adult women possess high knowledge and intention to participate in Pap testing after HPV vaccination. The vast majority of young adult women who received the HPV vaccine within its first two years on the market intend to participate in cervical cancer screening in the near future. Future studies are needed to examine whether those vaccinated in adolescence will become aware of, and adhere to, screening guidelines as they become eligible.
BACKGROUND: If women who receive the human papillomavirus (HPV) vaccine are unduly reassured about the cancer prevention benefits of vaccination, they may choose not to participate in screening, thereby increasing their risk for cervical cancer. This study assesses adult women's knowledge of the need to continue cervical cancer screening after HPV vaccination, describes Pap test intentions of vaccinated young adult women, and evaluates whether knowledge and intentions differ across groups at greatest risk for cervical cancer. METHODS: Data were from the 2008 Health Information National Trends Survey (HINTS) and the 2008 National Health Interview Survey (NHIS), which initiated data collection approximately 18 months after the first FDA approval of an HPV vaccine. We calculated associations between independent variables and the outcomes using chi-square tests. RESULTS: Of 1586 female HINTS respondents ages 18 through 74, 95.6% knew that HPV-vaccinated women should continue to receive Pap tests. This knowledge did not vary significantly by race/ethnicity, education, income, or healthcare access. Among 1101 female NHIS respondents ages 18-26 who had ever received a Pap test, the proportion (12.7%; n=139) who reported receipt of the HPV vaccine were more likely than those not vaccinated to plan to receive a Pap test within three years (98.1% vs. 92.5%, p<0.001). CONCLUSIONS: US adult women possess high knowledge and intention to participate in Pap testing after HPV vaccination. The vast majority of young adult women who received the HPV vaccine within its first two years on the market intend to participate in cervical cancer screening in the near future. Future studies are needed to examine whether those vaccinated in adolescence will become aware of, and adhere to, screening guidelines as they become eligible.
Authors: J Hsia; E Kemper; C Kiefe; J Zapka; S Sofaer; M Pettinger; D Bowen; M Limacher; L Lillington; E Mason Journal: Prev Med Date: 2000-09 Impact factor: 4.018
Authors: Debbie Saslow; Philip E Castle; J Thomas Cox; Diane D Davey; Mark H Einstein; Daron G Ferris; Sue J Goldie; Diane M Harper; Walter Kinney; Anna-Barbara Moscicki; Kenneth L Noller; Cosette M Wheeler; Terri Ades; Kimberly S Andrews; Mary K Doroshenk; Kelly Green Kahn; Christy Schmidt; Omar Shafey; Robert A Smith; Edward E Partridge; Francisco Garcia Journal: CA Cancer J Clin Date: 2007 Jan-Feb Impact factor: 508.702
Authors: Chun Chao; Michael J Silverberg; Tracy A Becerra; Douglas A Corley; Christopher D Jensen; Qiaoling Chen; Virginia P Quinn Journal: Am J Obstet Gynecol Date: 2016-10-14 Impact factor: 8.661
Authors: Christine M Pierce Campbell; Lynette J Menezes; Electra D Paskett; Anna R Giuliano Journal: Cancer Epidemiol Biomarkers Prev Date: 2012-05-03 Impact factor: 4.254
Authors: F Xavier Bosch; Claudia Robles; Mireia Díaz; Marc Arbyn; Iacopo Baussano; Christine Clavel; Guglielmo Ronco; Joakim Dillner; Matti Lehtinen; Karl-Ulrich Petry; Mario Poljak; Susanne K Kjaer; Chris J L M Meijer; Suzanne M Garland; Jorge Salmerón; Xavier Castellsagué; Laia Bruni; Silvia de Sanjosé; Jack Cuzick Journal: Nat Rev Clin Oncol Date: 2015-09-01 Impact factor: 66.675
Authors: Lisa M Higgins; Kelsie N Dirksing; Lili Ding; Charlene D Morrow; Lea A Widdice; Jessica A Kahn Journal: Hum Vaccin Immunother Date: 2016-03-02 Impact factor: 3.452
Authors: Tomoko Ito; Remi Takenoshita; Keiichiro Narumoto; Melissa Plegue; Ananda Sen; Benjamin Franklin Crabtree; Michael Derwin Fetters Journal: Asia Pac Fam Med Date: 2014-11-18
Authors: Mie Sara Hestbech; Dorte Gyrd-Hansen; Jakob Kragstrup; Volkert Siersma; John Brodersen Journal: BMC Public Health Date: 2016-08-03 Impact factor: 3.295
Authors: Amit G Singal; Jasmin A Tiro; Caitlin C Murphy; James-Michael Blackwell; Jennifer R Kramer; Aisha Khan; Yan Liu; Song Zhang; Jessica L Phillips; Ruben Hernaez Journal: Clin Gastroenterol Hepatol Date: 2020-07-03 Impact factor: 11.382
Authors: Christopher A Paynter; Benjamin J Van Treeck; Inge Verdenius; Agnes W Y Lau; Twinkle Dhawan; Kayla A Lash; Elizabeth A Bergamini; Chiazotam N Ekekezie; Amna M Hilal; Kristen N James; Sadie Alongi; Sean M Harper; Aaron J Bonham; Kathy B Baumgartner; Richard N Baumgartner; Diane M Harper Journal: Prev Med Rep Date: 2015-07-31